Eli Lilly to acquire Calytrix Bio in cash deal worth up to $1.5 billion

Eli Lilly agreed to buy privately held Calytrix Bio for a total consideration of up to $1.5 billion in cash. The transaction includes an undisclosed upfront payment and additional milestone‑based payments tied to clinical and regulatory achievements. Calytrix’s lead program is a preclinical biparatopic antibody that targets mutant calreticulin in essential thrombocythemia and myelofibrosis. Lilly’s shares rose about 1% after the announcement.

The acquisition adds a novel antibody platform to Lilly’s hematology pipeline, expanding its presence in rare blood‑cancer treatments. Analysts noted the deal helped lift Lilly’s stock, which rose over 1% on the news.

  • 1The total potential consideration for the transaction is up to $1.5 billion in cash.
  • 2The deal includes an undisclosed upfront cash payment and additional payments linked to the achievement of clinical and regulatory milestones.
  • 3Calytrix’s lead asset is a preclinical biparatopic antibody designed to target mutant calreticulin in essential thrombocythemia and myelofibrosis.
  • 4Lilly’s shares rose over 1% on Monday following the announcement.
  • 5Lilly’s stock closed at $1,443.50, up 1.26%.

Sources